

Appendix B. Sample Forms

B.1. Inclusion Criteria Worksheet: Acute migraine review

Reviewer ID:	Date: / /2011	Record ID:	
Criteria	Yes	No	UC
1. PUBLICATION TYPE no date restriction			
a. Report of primary research	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. STUDY DESIGN			
a. Efficacy and effectiveness: RCTs and NRCTs	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
b. Safety: RCTs, NRCTs, and prospective cohort studies	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. POPULATION			
a. Adult patients (≥ 18 years) with severe acute migraine headache presenting to an ED or equivalent setting and receiving parenteral therapy	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. INTERVENTION			
In-ED treatment:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
First-line parenteral (intravenous/intramuscular/ subcutaneous) interventions:			
a) Metoclopramide (Maxeran/Reglan);			
b) Dihydroergotamine (DHE);			
c) NSAIDs (ketorolac {Toradol});			
d) Phenothiazines (chlorpromazine {Largactil}, prochlorperazine {Stemtil}, droperidol);			
e) Magnesium sulphate (MgSO4);			
f) Triptan agents;			
g) Meperidine (Demerol);			
h) Valproic acid;			
i) Other agents: propafol (Diprivan), ketamine (Ketalar), opioids.			
Prevention of relapse:			
a) Parenteral corticosteroids (dexamethasone, others);			
b) Oral corticosteroids (prednisone, others)			
(Note corticosteroids must be used in addition to one of the parenteral interventions above)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. COMPARATOR GROUP			
In-ED treatment:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Any agent used as standard care, placebo, or an active comparator. Any route of administration.			
Prevention of relapse:			
Standard parenteral therapy (i.e., one of the interventions listed above) plus placebo or no treatment.			
6. OUTCOME			
1. Pain relief/change in pain score (measured either as Visual Analog Score {VAS}, a Likert scale of pain, or a 10-point verbal scale);	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Complete elimination of pain prior to ED discharge;			
3. Vital signs (i.e., blood pressure, pulse);			
4. Time in the ED (in minutes of total time and post-ED physician time).			
5. Recurrence of headache (headache relieved in the ED and recurring within the following period);			
6. Health services utilization (e.g. return visit to ED defined as an unscheduled visit for worsening symptoms);			
7. Patient satisfaction with experience;			
8. Quality of life/return to activities;			
9. Adverse effects of intervention(s) (e.g. sedation/somnolence; dizziness; restless legs/ akathisia; anxiety; vomiting; chest symptoms, palpitations; skin flushing; other side effects)			
Comments			
REVIEWER'S DECISION : Include <input type="checkbox"/> Exclude <input type="checkbox"/> Unsure <input type="checkbox"/>			
FINAL DECISION: Include <input type="checkbox"/> Exclude <input type="checkbox"/> Unsure <input type="checkbox"/>			